mk-2206

Colon Mucinous Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Colon Mucinous Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM University of Southern California	Phase 3	BBB
Irinotecan Fox Chase Cancer Center	Phase 3	BB
Eloxatin John Hays	Phase 3	BB
Cetuximab National Cancer Institute (NCI)	Phase 2	BB
Edrecolomab National Cancer Institute (NCI)	Phase 3	B

View all 18 →

Same molecule, other indications

mk-2206 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

BB

Indicative ·

64 / 100

diffuse large B-cell lymphomaDormant

B

Indicative ·

60 / 100

prostate cancerDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.